Kornimate/medical-research-clean huggingface dataset:
study of dotatate imaging in breast cancer

Conditions: Breast Cancer Stage IV

Summary: this will be a phase 2 clinical trial to assess somatostatin receptor (sstr) expression in stage iv estrogen receptor positive (er+) breast cancer using gallium-68 dotatate or copper-64 dotatate pet/ct.

subjects with metastatic breast cancer are planned to be enrolled to undergo gallium-68 dotatate or copper-64 dotatate pet/ct imaging at one time point. sstr uptake in metastatic lesions will be evaluated by independent central review (icr). fdg pet and bone scans will also be performed within +/- 3 weeks of dotatate imaging. the primary objective of this study is to evaluate uptake of gallium-68 dotatate or copper-64 dotatate in metastatic er+ breast cancer lesions.

Eligibility criteria:
inclusion criteria: * age of at least 18 years at the time of signing the informed consent. * biopsy proven, er+, her2 any, clinically progressive, stage iv breast cancer requiring restaging. * for women of childbearing potential (wocbp): a. negative serum pregnancy test within 48 hours of ga-68-dotatate injection. a women is considered to be of childbearing potential if she is post-menarchal, has not reached postmenopausal state (≥ 12 continuous months of amenorrhea \[no menstrual bleeding of any kind, including menstrual period, irregular bleeding, spotting, etc.\] with no identified cause other than menopause), and has not undergone surgical sterilization (total hysterectomy, or bilateral tubal ligation or bilateral oophorectomy at least 6 weeks before taking study drug). * willingness and ability to provide written informed consent prior to any study-specific assessments and procedures commence. exclusion criteria: * known hypersensitivity to gallium-68 dotatate or copper-64 dotatate, octreotate, or any of the excipients of gallium-68 dotatate or copper-64 dotatate * current high-dose glucocorticoid (≥ 20 mg prednisone daily or equivalent); long acting ssa within the last 28 days; short acting ssa that cannot be interrupted for 24 hours. * unable to perform pet/ct scans according to technical specifications and local guidelines. * concurrent primary malignancy, except adequately treated carcinoma in situ, non-melanoma carcinoma of the skin or any other curatively treated malignancy that has achieved complete response and is not expected to require treatment for recurrence during participation in the study. * current somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study. * unable or unwilling to comply with the requirements of the study protocol. * prior participation in any interventional clinical study within 30 days prior to sstr pet/ct scan.
prospective trial to evaluate the safety and efficacy to treat esophageal cancer using 5-fu, oxaliplatin, and docetaxel

Conditions: Esophageal Squamous Cell Carcinoma

Summary: the current multicenter prospective phase ii study aims to evaluate the safety and efficacy of preoperative flot therapy for esophageal squamous cell carcinoma.


Eligibility criteria:
inclusion criteria: 1. histologically diagnosed as esophageal squamous cell carcinoma (squamous, adenosquamous, basaloid) 2. primary tumor is located mainly in the thoracic esophagus 3. ct1n1-3m0-1 (only supraclavicular ln metastasis is included as m1), ct2-3n0-3m0-1 (only supraclavicular ln metastasis is included as m1) 4. twenty years old or older as of registration 5. performance status (ps) 0 or 1 6. patients have target lesions 7. no previous history of esophageal cancer except for the followings 1) pt1a-lpm (m2) or deeper following emr/esd 2) pt1a-mm (m3) with vascular invasion following emr/ esd 8. no previous history of chemotherapy/radiotherapy/endocrine therapy except for hormone therapy for prostate cancer after 5 years interval 9. patients who meet the following criteria 1. neutrophil \> 1,500 /mm3 2. platelet \> 10.0x10\^4 /mm3 3. hb ≧9.0 g/dl 4. total bilirubin ≦ 1.5 mg/dl 5. ast ≦ 100 iu/l 6. alt ≦ 100 iu/l 7. spo2 ≧ 95 % 8. creatinine clearance ≧ 50 ml/min 10. patients who can undergo esophagectomy 11. agree with the participation to the current study exclusion criteria: 1. patients who received any treatment for cancer within 3 years 2. patients who have active infectious diseases 3. hbs ag positive or hiv ab positive 4. pregnant or breast feeding 5. patients with psychological disorder 6. on systemic steroid therapy 7. require flucytocine, phenytoin, warfarin 8. allergic to iodine 9. allergic to dtx, lohp, polisorbate 80 10. uncontrollable diabetes 11. severe copd or lung fibrosis 12. severe hypertension 13. unstable angina 14. patients whom investigators evaluate as ineligible
prognostic value of cardial stress perfusion imaging

Conditions: Coronary Artery Disease

Summary: stress myocardial perfusion scintigraphy is a reference examination for the detection and monitoring of coronary patients, and this examination has already been the subject of multiple validation studies, including for the stratification of the prognosis of these patients, information that can usefully guide therapeutic choices. today, this reduction in the activity of injected radiopharmaceuticals is taking place in a growing number of nuclear medicine departments. the implications are unknown in terms of the risk of death of the different parameters studied

stress myocardial perfusion scintigraphy is a reference examination for the detection and monitoring of coronary patients, and this examination has already been the subject of multiple validation studies, including for the stratification of the prognosis of these patients, information that can usefully guide therapeutic choices (medical treatment, myocardial revascularization, ...). the arrival of new solid-state cameras has been a real technological leap for this examination, making it possible to significantly improve the quality of the images and also to drastically reduce the activities of injected radiopharmaceuticals and thus the exposure of patients and staff to ionizing radiation. today, this reduction in the activity of injected radiopharmaceuticals is taking place in a growing number of nuclear medicine departments. the injected activities are reduced up to a third of those injected in the past (this is indeed the case in the population we propose to study). however, the value of the prognostic stratification obtained with stress myocardial perfusion scans recorded with low activity on semiconductor cameras is not yet known. in particular, the implications are unknown in terms of the risk of death of the different parameters studied (normal or abnormal examination, extent of myocardial ischemia and infarction sequelae, impact on left ventricular function in post-stress and resting states, etc.).

Eligibility criteria:
inclusion criteria: * any coronary patient suspected or proven to have had a stress myocardial perfusion tomoscintigraphy performed at the nancy chru and corresponding to a standardized model of expression of results (i.e. more than 10,000 reports). exclusion criteria: * none

Keywords: coronary myocardial perfusion tomoscintigraphy.
a clinical trial of omacetaxine, azacitidine, and growth-colony stimulating factor (g-csf) for myelodysplastic syndromes (mds)

Conditions: Myelodysplastic Syndromes

Summary: the purpose of this study is to determine the safety and establish the maximum tolerated dose (mtd) of omacetaxine in combination with azacitidine and g-csf in patients with relapsed and/or refractory mds.


Eligibility criteria:
inclusion criteria: * age \>= 18 years; * informed consent; * low- and intermediate-risk mds that has failed to achieve any hematologic improvement after at least 4 cycles of induction therapy or has relapsed after any duration of any hematologic response. prior therapy with azanucleosides (i.e., azacitidine, decitabine), biologic therapies (i.e., lenalidomide, rigosertib) and hematopoietic cell transplant are permissible; * performance status must be eastern cooperative oncology group (ecog) 0, 1, or 2; * women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) may participate, provided they meet the following conditions: * must agree to use physician-approved contraceptive methods throughout the study and for three months following the last dose of omacetaxine and * must have a negative serum or urine pregnancy test within 7 days prior to beginning treatment on this trial; * males with female partners of child-bearing potential must agree to use physician-approved contraceptive methods throughout the study and should avoid conceiving a child for 6 months following the last dose of omacetaxine. exclusion criteria: * subjects who are eligible for hematopoietic stem cell transplant; * history of atrial fibrillation related to azanucleoside therapy in the past; * active, uncontrolled, clinically significant infection; * pregnant and nursing patients are excluded because the effects of omacetaxine on a fetus or nursing child are unknown; * treatment with any anticancer therapy (standard or investigational) within the previous 14 days prior to the first dose of study drug or less than full recovery from the clinically significant toxic effects of that treatment.

Keywords: myelodysplastic syndromes
survival with patients treated with salivary gland cancer

Conditions: Salivary Gland Cancer; Salivary Gland Neoplasms

Summary: salivary gland malignancies is very heterogenous group of tumors regarding tumor histology and localization. the aim of this study is to assess main clinical and pathological parameters related to patients survival

the retrospective study enrolled medical charts of the patients treated due to salivaly gland cancers in the clinic for maxillofacial surgery at clinical center of vojvodina in the period of 1. january 1996. to 31. december 2021. patients demographics, type of the tumor, localization, tnm status and patohystological parameters were evaluated for patients survival and disease free periods

Eligibility criteria:
inclusion criteria: patients with salivary gland malignancies treted in the clinic for maxillofacial surgery exclusion criteria: incomplete medical data patients with metastatic tumord of salivary gland patients with recurrent malignancies of salivary glands sent from other clinics

Keywords: salivary gland cancer survival prognostic factors
quality of life in systemic nickel allergy syndrome

Conditions: Systemic Nickel Allergy Syndrome; Quality of Life

Summary: this study evaluates the effects of nickel oral hyposensitization treatment (nioht) on health-related quality of life (hrqol) of patients suffered from systemic nickel allergy syndrome (snas).

nickel (ni) is a nutritionally essential metal widely distributed in the environment, and it has been reported to be one of the most common causes of allergic contact dermatitis (acd), affecting nearly 15-20% of the general population. as known, ni-hypersensitivity can induce less frequently also respiratory allergy (ra) and in approximately 20% of ni-acd patients cause a more complex condition termed systemic nickel allergy syndrome (snas). it is characterized by a combination of cutaneous (in regions without direct nickel contact) and extracutaneous gastrointestinal symptoms, after the ingestion of ni-rich foods, especially vegetables. then, a low-ni diet, following positive patch tests, represents a effective diagnostic and therapeutic tool in the control of systemic manifestations, determining a significant clinical improvement. it is known that nickel oral hyposensitization treatment (nioht) is a effective approach for the management of ni allergy, especially in a subset of patients with snas, inducing immunological and clinical tolerance to metal at the doses normally taken with the diet. although a large number of clinical trials focused on the health-related quality of life (hrqol) in allergic disease, the expectations, the needs and the psychosocial characteristics of patients affected by snas are limited and no data exist pre- and post-treatment and specifically with nioht. given the high safety profile and beneficial effects of immunotherapy on hrqol of patients with allergic rhinitis, we hypothesized similar positive results even after oral ni desensitization.

Eligibility criteria:
inclusion criteria: * history of snas (coexistence of typical cutaneous and gastrointestinal symptoms), * positive ni-patch test, * clinical improvement at least 70% from baseline after 4 weeks on a low-ni diet, * positivity of a double blind placebo-controlled oral ni challenge (dbpco), * written informed consent. exclusion criteria: * age \ 65 years, * other organic gastrointestinal diseases, such as peptic ulcer, inflammatory bowel diseases, celiac disease, gastrointestinal infections, and small intestinal bacterial overgrowth, * diabetes mellitus, * hepatic, renal or cardiac dysfunction, * thyroid disease or tumor, * concomitant treatment with steroids and/or antihistamines in the previous 4 weeks, pregnancy, lactation, * smoking, abuse of alcohol, coffee, tea, and cola intake, * refusal to participate.

Keywords: nickel allergy systemic nickel allergy syndrome health-related quality of life nickel oral hyposensitizing treatment diet short-form 36-item health survey psychological general well being index minnesota multiphasic personality inventory
anti-angiogenesis agent ag-013736 in patients with advanced non-small cell lung cancer

Conditions: Lung Neoplasms; Carcinoma, Non-small Cell Lung

Summary: this is a phase 2 study being conducted at multiple centers in the united states and germany. patients having non-small cell lung cancer that has spread to other parts of the body (i.e., metastatic) or is locally advanced (i.e., stage iiib with malignant pleural effusion) are eligible to participate. patients must have disease that has been treated with at least 1 prior treatment for metastatic disease (prior adjuvant treatment for localized disease does not count as prior treatment for metastatic disease). the purpose of the study is to test whether the angiogenesis inhibitor ag-013736 is an effective treatment for advanced non-small cell lung cancer as shown by the number of patients in the study who experience significant and durable tumor shrinkage


Eligibility criteria:
inclusion criteria: * histologically documented non-small cell lung cancer with metastases (stage iv or recurrent disease) or locally advanced (stage iiib) with malignant pleural effusion. * at least 1 prior systemic therapy for metastatic disease (prior adjuvant therapy for localized disease does not count as a prior therapy for metastatic disease). exclusion criteria: * central lung lesions involving major blood vessels (arteries or veins). (central lesions that maintain the structural integrity of vessels have the potential to bleed if the tumor lesion undergoes necrosis. mri or ct angiography should be used in any case where there is any question as to whether blood vessels are involved.) * patients with a history of grade 2 or worse hemoptysis are not eligible. patients with a history of grade 1 hemoptysis within 30 days of entry are not eligible
aerobic training, aerobic-resistance training and glucose profile (cgms) in type 2 diabetes

Conditions: Diabetes Mellitus, Type 2; Treatment; Exercise

Summary: many studies were already performed showing beneficial cardiovascular and metabolic effects of physical training for type 2 diabetic patients. however, glucose profile during and immediately after a short period of aerobic and/or resistance training was not studied yet. continuous glucose monitoring system (cgms) has now been added to the repertoire of technological devices useful in the management of patients with diabetes. such monitoring enables clinicians to detect occult hypoglycemia and hyperglycemia not otherwise discernable with intermittent testing of blood glucose. the main aim of the present study is to investigate continuous blood glucose profile (using cgms) over 72h, beginning 24h before and ending 24h after a single bout of aerobic or aerobic/resistance physical training in type 2 diabetic patients.

many studies were already performed showing beneficial cardiovascular and metabolic effects of physical training for type 2 diabetic patients. however, glucose profile during and immediately after a short period of aerobic and/or resistance training was not studied yet. continuous glucose monitoring system (cgms) has now been added to the repertoire of technological devices useful in the management of patients with diabetes. such monitoring enables clinicians to detect occult hypoglycemia and hyperglycemia not otherwise discernable with intermittent testing of blood glucose. the main aim of the present study is to investigate continuous blood glucose profile (using cgms) over 72h, beginning 24h before and ending 24h after a single bout of aerobic or aerobic/resistance physical training in type 2 diabetic patients.

Eligibility criteria:
inclusion criteria: * type 2 diabetic patients treated with diet and metformin, 35-65 years old exclusion criteria: * type 1 diabetic patients * treatment with insulin or sulphonylureas or glitazones * proliferative retinopathy * severe autonomic neuropathy * coronary artery disease * baseline fasting plasma glucose\>200 mg/dl * peripheral artery disease * amputation * heart failure * diabetic nephropathy * renal failure

Keywords: diabetes mellitus exercise endurance resistance continuous glucose monitoring system
salivary bacteria and oral health status in children with adhd

Conditions: Attention Deficit Hyperactivity Disorders; Caries, Dental; Xerostomia

Summary: attention deficit and hyperactivity (adhd) affect 6% of school-aged children. few studies reported higher prevalence of caries and restorations among children with adhd. methylphenidate is the drug of choice to treat adhd. according to the medical literature methylphenidate can cause xerostomia. our study will investigate saliva parameters (such as quantity, bacteria in saliva, buffer capacity), oral hygiene and diet habits and their influence on caries among children with adhd and among healthy children. our hypothesis is: * children with adhd will have more caries. * children with adhd will have more detrimental oral hygiene and diet habits. * there will be a difference in the saliva parameters between children with adhd and healthy children.


Eligibility criteria:
inclusion criteria: * test group- diagnosis of adhd. * control group- asa1 exclusion criteria: * control group * administration of medicine at the time of the check-up.

Keywords: adhd, saliva, caries
safety and efficacy study of syn115 in parkinson's patients using levodopa to treat end of dose wearing off

Conditions: Parkinson's Disease

Summary: the purpose of this research study is to test the effect of syn115 compared to placebo (a "sugar pill" that looks like syn115 but does not include active drug) on movement during the "on" and "off" states as well as other symptoms that some patients with parkinson's disease experience. this study will also look at whether or not patients with parkinson's disease experience "side-effects" with syn115.


Eligibility criteria:
inclusion criteria: * meet parkinson's disease (pd) diagnosis consistent with uk pd diagnostic criteria * meet hoehn and yahr pd stage * good response to levodopa * stable regimen of anti-parkinson medications * are able to complete a parkinson's disease diary * if of childbearing potential(male and female), use an acceptable method of birth control * able and willing to sign an irb/iec approved informed consent * able and willing to understand study requirements, follow study instructions, attend all visits and undergo all planned tests. exclusion criteria: * secondary or atypical parkinson's * neurosurgical intervention for parkinson's disease * treatment with apomorphine * treatment with anti-psychotic drugs * other abnormal findings on physical or neuro exam or history that in the opinion of the investigator would make subject unsuitable for the study or prejudice safety and efficacy evaluation * mmse less than 26 * subjects with untreated or uncontrolled current episode of major depression * receipt of any anti-psychotic drugs greater than 1 month in the past 5 years or any exposure in past year (except for quetiapine at doses \<100mg per day) * women pregnant or lactating * history of hepatitis, cholangitis * untreated or uncontrolled hypothyroidism or hyperthyroidism * drops in blood pressure requiring medication to maintain blood pressure * any clinically significant out of range laboratory evaluations * known sensitivity to the study medication or its components * suicide ideation or type 4 or type 5 on the columbia suicide severity rating scale * finding of malignant melanoma on full body skin exam * impulse disorder conditions
evaluating public health interventions to improve covid-19 testing among underserved populations

Conditions: COVID-19

Summary: the covid-19 pandemic has disproportionately affected people from underserved and vulnerable populations such as low-income/uninsured, unhoused, and immigrant communities. these populations in the us are at a higher risk of acquiring covid-19 because of poverty, type of occupation, greater use of public transit, living in multigenerational housing, lack of access to quality healthcare, and more. despite greater risk of being infected and dying of covid-19, those in disadvantaged communities are less likely to get tested. the investigators are collaborating with community partners in cumberland county, maine to implement a public health intervention focused on making covid-19 testing more accessible to underserved populations. the intervention includes a one-time in-person training on how to take an at-home covid-19 test and then provision of at-home covid-19 testing kits to make testing more accessible. five testing kits are provided at the time of training and then provided every two months for a year, for a total of 35 testing kits. in this study, the investigators will evaluate the impact of the at-home testing kit intervention on covid-19 testing behavior, knowledge and attitudes. the investigators will accomplish this aim by following a community cohort, with a goal of recruiting 150 participants - 15 participants from each of our 10 population groups of interest (three groups that access different health services for low-income/uninsured, unhoused individuals, and six different immigrant groups). the investigators will administer surveys to the cohort participants every month over a 12 month period. every month the survey will ask about testing behavior, and every other month the survey will also ask about knowledge and attitudes towards testing. in order to ensure access to covid-19 tests, the cohort participants will be provided at-home testing kits throughout the course of the study. the primary outcome of interest is "recommended testing behavior," which is defined as taking a rapid covid-19 test when experiencing symptoms of covid-19 or after a close contact exposure. the investigators hypothesize that knowledge about testing, favorable attitudes towards testing, and recommended testing behavior will increase as a result of participation in the study.


Eligibility criteria:
inclusion criteria: * individual accesses services from one of these three public health facilities - community free clinic, needle exchange program, or std clinic * individual is currently unhoused or living in a housing first development * individual immigrated to the us, primarily from one of these six country groups - somalia, angola, iraq or syria, burundi or rwanda, democratic republic of the congo, or a country in latin america exclusion criteria: • individual is \<18 years old

Keywords: covid-19 testing low-income populations immigrant populations unhoused populations uninsured populations